Senesco Announces Letter of Intent to Merge with Fabrus

06-01-2014 Business Wire HealthComments (0)

BiotechnologyFabrus

Related Companies

Senesco Technologies, Inc (OTCQB:SNTI), today announced that it has agreed to terms and executed a non-binding Letter of Intent to merge with Fabrus, Inc, a privately-held, biotechnology company focused on expanding the clinical impact of antibodies by addressing drug targets resistant to traditional antibody discovery methods. Fabrus is committed to developing highly innovative treatments to impact multiple diseases.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top